JoshepbenExscientia to start world-first trials of AI-designed immuno-oncology drugOxford-based artificial intelligence drug disclosure firm Exscientia is getting ready to start Stage I clinical preliminaries with the…Nov 16, 2022Nov 16, 2022
JoshepbenCharcot-Marie-Tooth Disease Type I A Drugs | Market sizeCharcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview…May 27, 2022May 27, 2022
JoshepbenBeta 3 Adrenergic Receptor Drugs | Market sizeBeta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA…May 27, 2022May 27, 2022
JoshepbenAngiotensin Converting Enzyme Drugs | Market sizeAngiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) Drugs in…May 27, 2022May 27, 2022
JoshepbenCells Expressing Leukocyte Antigen CD37 Drugs | Market sizeCells Expressing Leukocyte Antigen CD37 (Tetraspanin 26 or CD37) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA…May 27, 2022May 27, 2022